India, Nov. 18 -- Scribe Therapeutics Inc. (SCTX) presented new preclinical data from its STX-1150 and STX-1200 programs at the American Heart Association (AHA) Scientific Sessions 2026, highlighting the potential of its investigational genetic medicines to provide long-lasting reductions in cholesterol and other cardiovascular risk factors.
A single dose of an STX-1150 prototype lowered LDL cholesterol (LDL-C) by more than 50% for at least two years in non-human primates.
The treatment achieved reductions of up to 68%, without permanently changing DNA. Additional studies showed that repeat dosing led to further LDL-C reductions while remaining well tolerated.
STX-1150 is an investigational CRISPR-based therapy designed to reduce product...